ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The firm is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. The company is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.
Follow-Up Questions
ProKidney Corp의 CEO는 누구입니까?
Dr. Bruce Culleton은 2023부터 회사에 합류한 ProKidney Corp의 Chief Executive Officer입니다.
PROK 주식의 가격 성능은 어떻습니까?
PROK의 현재 가격은 $2.91이며, 전 거래일에 increased 4.07% 하였습니다.
ProKidney Corp의 주요 사업 주제나 업종은 무엇입니까?
ProKidney Corp은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
ProKidney Corp의 시가총액은 얼마입니까?
ProKidney Corp의 현재 시가총액은 $857.5M입니다
ProKidney Corp는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 8명의 분석가가 ProKidney Corp에 대한 분석 평가를 실시했으며, 이는 5명의 강력한 매수, 4명의 매수, 4명의 보유, 1명의 매도, 그리고 5명의 강력한 매도를 포함합니다
